Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market

CAMBRIDGE, Mass., Dec. 20, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective before market open on December 23, 2013.  Epizyme also announced that its common stock will be transferred to the NASDAQ Global Select Market effective January 2, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index.  In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.

The NASDAQ Global Select Market is the top listing tier for NASDAQ companies, with the highest initial listing standards in the world.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.

SOURCE Epizyme, Inc.